Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indibulin + erlotinib
- Development stage
- Phase 1
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of **indibulin**, a small molecule inhibitor of microtubule dynamics, and **erlotinib**, a small molecule EGFR tyrosine kinase inhibitor. Indibulin disrupts mitotic spindle formation, thereby inhibiting cell division and inducing apoptosis in cancer cells. Erlotinib targets the epidermal growth factor receptor (EGFR), inhibiting its tyrosine kinase activity and thus blocking the downstream signaling pathways involved in cell proliferation and survival. This combination is under investigation for the treatment of advanced solid tumors, particularly metastatic breast cancer and other refractory cancers. Preclinical and phase I studies suggest possible synergistic cytotoxicity[1][5].
- Brand names
- erlotinib (Tarceva)
- Other names
- indibulin + erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on indibulin + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indibulin + erlotinib.